Stay updated on Imetelstat Activity in JAK-Inhibitor-Treated MF Clinical Trial
Sign up to get notified when there's something new on the Imetelstat Activity in JAK-Inhibitor-Treated MF Clinical Trial page.

Latest updates to the Imetelstat Activity in JAK-Inhibitor-Treated MF Clinical Trial page
- CheckyesterdayChange DetectedThe study record no longer displays the 2015 U.S. NIH grant/contract identifier, and the site revision label changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe record describes a completed Phase 2 study of two imetelstat dose regimens for higher-risk myelofibrosis after JAK inhibitor treatment. It includes study design and outcome measures, eligibility criteria, locations, posted results, and study documents.SummaryDifference73%

- Check22 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedAn NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” across NIH content. The study record itself remains unavailable behind a 403 error.SummaryDifference1%

- Check36 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Imetelstat Activity in JAK-Inhibitor-Treated MF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imetelstat Activity in JAK-Inhibitor-Treated MF Clinical Trial page.